Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
The aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina.
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | Argentina |
| Institución: | Universidad Nacional de La Plata |
| Repositorio: | SEDICI (UNLP) |
| Idioma: | inglés |
| OAI Identifier: | oai:sedici.unlp.edu.ar:10915/156981 |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/156981 |
| Access Level: | acceso abierto |
| Palabra clave: | Ciencias Médicas venetoclax plus obinutuzumab lymphocytic leukemia |
| Sumario: | The aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina. |
|---|